MorphoSys Out-licenses Two Oncology Antibodies to HIBio
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)
Published: 20 Jun-2022
DOI: 10.3833/pdr.v2022.i6.2697 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In an attempt to reorganise its oncology pipeline, MorphoSys has entered into a license agreement with Human Immunology Biosciences (HIBio) to develop and commercialise MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS